Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10930258 | 0.98 | PPARA (0.61) | PPARAEPHX1CA2CA1CA12 | |
| SCHEMBL11221936 | 0.98 | PPARA (0.61) | PPARAEPHX1CA2CA1CA12 | |
| SCHEMBL3365101 | 0.92 | — | — | |
| SCHEMBL1111454 | 0.81 | — | — | |
| SCHEMBL2882733 | 0.79 | PPARA (0.62) | PPARAEPHX1CA2CA1CA12 | |
| SCHEMBL4563383 | 0.79 | PPARA (0.86) | PPARAEPHX1CA2CA1CA12 | |
| SCHEMBL9285865 | 0.77 | PPARA (0.91) | PPARAEPHX1CA2CA1CA12 | |
| SCHEMBL694651 | 0.77 | PPARA (0.60) | PPARAEPHX1CA2CA1CA12 | |
| SCHEMBL5256485 | 0.77 | PPARA (0.67) | PPARAEPHX1CA2CA1CA12 | |
| SCHEMBL327308 | 0.77 | PPARA (0.60) | PPARAEPHX1CA2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| EP-4121031-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | Atux Iskay LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021188949-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021150697-A1 | N-SUBSTITUTED-3-TRICYCLYL PIPERIDINE DERIVATIVES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021116050-A1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-17 | — | — | WO | disclosed |
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-3019492-B1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-3019492-A1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | Boehringer Ingelheim International GmbH (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-5668279-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DIORDERS AND GASTROINTESTINAL DISORDERS | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0666851-A4 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS. | — | 1995-08-30 | — | — | EP | disclosed |
| EP-0666851-A1 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS | MERCK & CO. INC. (US) | 1995-08-16 | — | — | EP | disclosed |
| US-5411980-A | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5312820-A | Angiotensin antagonist for treatment of hypertension | MERCK & CO., INC. (US) | 1994-05-17 | — | — | US | disclosed |
| WO-1994010151-A1 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-4327034-A | CHEMICAL INTERMEDIATE PREPARED FROM A SULFAMIC ACID HALIDE AND A HALOGEN COMPOUND | BASF AKTIENGESELLSCHAFT (DE) | 1982-04-27 | — | — | US | disclosed |
| US-3992444-A | BY REACTION OF A SULFAMIC ACID WITH AN ACID HALIDE | BASF AKTIENGESELLSCHAFT (DT) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308605-B2 | Proton pump inhibitors | HRH2, HRH4, HRH1 | PPARA 1914/4885EPHX1 1288/4885CA2 1157/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | PPARA 813/4885EPHX1 1901/4885CA2 4187/4885 |
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | PPARA 2231/4885EPHX1 4710/4885CA2 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.